CV Sciences Inc (CVSI)
OTHER OTC:CVSI
Want to see CVSI full AI Analyst Report?
Earnings Data
Report Date
Aug 17, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
>-0.01Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Q1 2026
Earnings Call Date:May 08, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call highlights meaningful operational progress: year-over-year margin expansion, a ~13% reduction in operating expenses, improved adjusted EBITDA (loss narrowed to $0.1M), and a notable shift to positive operating cash flow. Management is actively diversifying into non-cannabinoid health products, launching new SKUs, insourcing manufacturing, and integrating recent acquisitions to realize synergies in H2 2026. However, revenue trends remain a concern (down 11% YoY, unit sales down ~12%), GAAP net loss widened to $0.6M, cash on hand is low (~$0.3M), and regulatory uncertainty persists and could require product changes. On balance, the operational and financial improvements and strategic initiatives provide a constructive trajectory toward profitability and cash flow breakeven, outweighing the top-line and regulatory challenges in the near term.Company Guidance
Revenue Resilience Despite Headwinds
Revenue of $3.2M for Q1 2026, only down 3% sequentially from Q4 2025 and down 11% year-over-year, demonstrating resilience in a difficult operating and regulatory environment.
Improved Gross Margin Year-over-Year
Gross margin expanded to 48.9% in Q1 2026 versus 46.0% in Q1 2025 (improvement of 2.9 percentage points), driven by lower product costs and progress insourcing manufacturing.
Meaningful Cost Reductions
Operating expenses (SG&A) declined roughly 13.3% to $1.9M compared with the prior year period, driven by lower legal/professional fees, reduced marketing spend and administrative efficiencies.
Adjusted EBITDA and Cash Flow Improvement
Adjusted EBITDA loss improved to $0.1M (loss) in Q1 2026 from a $0.3M loss in Q1 2025. The company generated positive operating cash flow of approximately $0.1M versus operating cash usage of ~$0.1M in the prior year period.
Progress Toward Cash Flow Breakeven and Balance Sheet Actions
Company is approaching cash flow breakeven, ended Q1 with approximately $0.3M cash (slightly higher than year-end 2025), and amended a note payable into a convertible-note structure to improve financial flexibility.
Product and Channel Momentum
Launched PlusHLTH EMPOWR (20g protein, 5g creatine, probiotics) and announced multiple non-cannabinoid product plans for 2026. Direct-to-consumer channel remains strong at 44% of revenue and early consumer/retailer feedback for new products is encouraging.
Strategic M&A and Operational Insourcing
Acquisitions of Cultured Foods and Elevated Softgels contributing to scale, diversification, and supply chain flexibility; strategic insourcing of manufacturing expected to lower costs and speed time-to-market with synergies anticipated in H2 2026.
Market Position and Regulatory Tailwinds
Maintained #1 selling Hemp extract brand in natural product retail per SPINS. Federal developments: CMS BEI program (up to $500 annually for eligible hemp-derived products) and an FDA limited enforcement-discretion letter provide early regulatory clarity and potential new channels.
Inventory and Working Capital Management
Inventory reduced to $3.9M from $4.1M at year-end, reflecting tighter working capital management and improved collections and payables oversight.
CVSI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CVSI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2026 | $0.03 | $0.03 | -3.33% |
Mar 26, 2026 | $0.03 | $0.03 | 0.00% |
Nov 13, 2025 | $0.03 | $0.03 | 0.00% |
Aug 13, 2025 | $0.04 | $0.04 | +2.63% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does CV Sciences Inc (CVSI) report earnings?
CV Sciences Inc (CVSI) is schdueled to report earning on Aug 17, 2026, TBA (Confirmed).
What is CV Sciences Inc (CVSI) earnings time?
CV Sciences Inc (CVSI) earnings time is at Aug 17, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CVSI EPS forecast?
Currently, no data Available